Form 4: Vaxcyte CFO Andrew Guggenhime Executes Stock Option and Sells Shares Under 10b5-1 Plan

Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On December 18, 2024, Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised options to acquire 8,000 shares of common stock at a price of $5.35 per share.
• Concurrently, Guggenhime sold a total of 8,000 shares of Vaxcyte common stock in multiple transactions.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 17, 2024.
• The sale prices ranged from $87.256 to $90.41 per share.
• Following these transactions, Guggenhime directly owns 109,491 shares of Vaxcyte common stock and holds options for 262,827 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing plan, which is a normal course of business. There's no indication of positive or negative implications for the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

Insider trading activity is closely monitored in the biotech industry, especially for companies like Vaxcyte that are in the development stage and heavily reliant on investor confidence. Rule 10b5-1 plans are a common tool used by executives to diversify their holdings while avoiding accusations of trading on inside information.

Comparison to Industry Standards

• Comparing the trading activity to similar biotech companies, it's common for executives to utilize 10b5-1 plans for regular stock sales.
• For example, executives at companies like Moderna or BioNTech often have similar plans in place.
• The size and frequency of the transactions are within the typical range for a CFO of a company with Vaxcyte's market capitalization.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the existence of the 10b5-1 plan mitigates this risk.

Key Dates